Navigation Links
Amarantus BioSciences Demands Cessation of Unauthorized Listing on Berlin-Bremen Stock Exchange
Date:11/26/2012

n of trading on the BBSE will have no impact whatsoever on trading in the Company's common stock on the OTCQB trading platform where the Company currently trades in the United States, and the Company's trading symbol in the United States will remain AMBS.

About JS Barkats, PLLC

JS Barkats PLLC is a dynamic full-service law firm headquartered in the heart of New York specializing in Corporate, Capital Markets and Securities law. JS Barkats, principally represents both established and publicly traded emerging growth companies, both domestic and foreign, in a wide variety of industries. With 22 attorneys located in Alabama, New York, and Florida the firm's synergy between its strong securities and commercial litigation group and its experienced corporate securities team, as well as an established IP department represents, public companies,  venture capital firms, start-ups, life sciences companies, investment banking institutions, broker dealers, celebrities and high net worth individuals and other investors. For more information visit: www.JSBarkats.com  

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008.  The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases.  The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorder
'/>"/>

SOURCE Amarantus BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OneMedPlace Releases Update to Research Report on Amarantus Biosciences Focused on New Positive Ischemic Heart Disease Efficacy Data for MANF in Animals
2. Amarantus BioSciences Wins MANF Patent Challenge in Europe
3. Amarantus BioSciences Issues CEO Letter to Shareholders
4. Amarantus BioSciences Secures $1.1 Million in Financing
5. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
6. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
7. Amarantus BioSciences Corporate Overview to be Webcast Live Today from OneMedForum 2012 Conference in NYC
8. TheStockRadio.com Interviews Amarantus BioSciences President & CEO Gerald E. Commissiong
9. Amarantus BioSciences Featured in BioWorld Today, Brewer Sports Symposium and Opportunist Magazine
10. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
11. IntelliCell BioSciences Announces Michael Hershman Joins the IntelliCell BioSciences Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Gene synthesis and bioengineering company ... into a technology access and services agreement with ... proprietary protein engineering technology, known as “ProteinGPS®” to ... extremely excited that the global leader ADM has ... bioengineering technology has now been validated through many ...
(Date:12/17/2014)... FRANCISCO, Calif. , Dec. 17, 2014 /PRNewswire/ ... of a Phase 2 study evaluating the investigational ... treatment of patients with severe, chronic itch who ... standard of care, including topical steroids and antihistamines. ... percent change in Visual Analog Scale (VAS) itch ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... December 12, 2014 Clarassance, a privately ... its new name: Therabron Therapeutics , Inc. The ... bronchioles (a type of structure in the lungs similar ... mission to develop novel protein therapeutics for the treatment ... decided to change the name to mark the company's ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Production Efficiency and Manage Quality at New LIFE Nutrition ... Honeywell (NYSE: HON ) today announced that ... global manufacturer of healthcare products, to provide process control ... nutrition and infusion therapy solutions. The Leading Infusion Factory ...
... 27 Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE ... Vice President of Research and Development, will be presenting pre-clinical ... Meeting of the American Society of Gene Therapy, which is ... Diego, CA, from Wednesday, May 27th through to Saturday, May ...
... MONICA, Calif., May 27 Cord Blood America, Inc. (OTC ... company ( http://www.cordblood-america.com ) focused ... families nationwide and internationally, said today that it has reduced ... the first five months of 2009. "On April 6th, ...
Cached Biology Technology:Honeywell to Help B. Braun Healthcare Company Double Manufacturing Capacity of Life-Critical Products 2Honeywell to Help B. Braun Healthcare Company Double Manufacturing Capacity of Life-Critical Products 3Honeywell to Help B. Braun Healthcare Company Double Manufacturing Capacity of Life-Critical Products 4Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Gene Therapy 2Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Gene Therapy 3Cord Blood America Says Debt Reduced $4.194 Million in 2009 2
(Date:12/10/2014)... 8, 2014 You,ve been here before: you desperately ... remember your password, site key or the answer to your ... grade teacher? Today, Hoyos Labs , ... that will finally put an end to the frustration that ... . 1U leverages a user,s smartphone to acquire his ...
(Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for ... Medicine. Funding for this $50 million capital project is ... publicly launched next summer. The medical ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ... with plans to be ready to welcome medical students ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... the first study of its kind, researchers at Queens ... that low socioeconomic status (SES) and maternal gestational diabetes ... deficit hyperactivity disorder (ADHD) in six year olds. The ... Archives of Pediatrics and Adolescent Medicine , one ...
... of a microRNA promotes progressive muscle deterioration in a ... a study published online on January 2 in the ... As DMD patients age, their damaged muscle cells ... fibrosis is partly induced by the growth factor TGF-beta, ...
... Millbrook, N.Y. -- On January 2nd, WAMC Northeast Public Radio ... new radio show called Earth Wise: A look at our ... among radio listeners, with a focus on raising awareness about ... segments will air Monday through Friday at 11:10 AM and ...
Cached Biology News:Gestational diabetes and low socioeconomic status raise risk of ADHD in children 2A firmer understanding of muscle fibrosis 2Cary Institute and WAMC debut new environment radio show 2
... A very potent Rnase ... effective over a broad range ... This protein does not inhibit ... polymerase, AMV and M-MLV reverse ...
... The BioLogic Maximizer kit, 110 ... and pH monitoring and doubles flow ... DuoFlow chromatography systems. The kit includes ... Maximizer mixer, starter kit, tubing kit, ...
Mouse monoclonal antibody to QDPR - quinoid dihydropteridine reductase...
Mouse polyclonal antibody to QDPR - quinoid dihydropteridine reductase...
Biology Products: